Summary
In addition to recognizing and repairing mismatched bases in DNA, the mismatch repair (MMR) system also detects cisplatin DNA adducts and loss of MMR results in resistance to cisplatin. A comparison was made of the ability of MMR-proficient and -deficient cells to remove cisplatin adducts from their genome and to reactivate a transiently transfected plasmid that had previously been inactivated by cisplatin to express the firefly luciferase enzyme. MMR deficiency due to loss of hMLH1 function did not change the extent of platinum (Pt) accumulation or kinetics of removal from total cellular DNA. However, MMR-deficient cells, lacking either hMLH1 or hMSH2, generated twofold more luciferase activity from a cisplatin-damaged reporter plasmid than their MMR-proficient counterparts. Thus, detection of the cisplatin adducts by the MMR system reduced the efficiency of reactivation of the damaged luciferase gene compared to cells lacking this detector. The twofold reduction in reactivation efficiency was of the same order of magnitude as the difference in cisplatin sensitivity between the MMR-proficient and -deficient cells. We conclude that although MMR-proficient and -deficient cells remove Pt from their genome at equal rates, the loss of a functional MMR system facilitates the reactivation of a cisplatin-damaged reporter gene.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aebi, S., Kurdi-Haidar, B., Gordon, R., Cenni, B., Zheng, H., Fink, D., Christen, R. D., Boland, C. R., Koi, M., Fishel, R. & Howell, S. B. (1996). Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56: 3087–3090.
Aebi, S., Fink, D., Gordon, R., Kim, H. K., Zhen, H., Fink, J. L. & Howell, S. B. (1997). Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res 3: 1763–1767.
Ali-Osman, F., Berger, M. S., Rairkar, A. & Stein, D. E. (1994). Enhanced repair of a cisplatin-damaged reporter chloramphenicol-O-acetyltransferase gene and altered activities of DNA polymerases alpha and beta, and DNA ligase in cells of a human malignant glioma following in vivo cisplatin therapy. J Cell Biochem 54: 11–19.
Andrews, P. A., Jones, J. A., Varki, N. M. & Howell, S. B. (1990). Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun 2: 93–100.
Boyer, J. C., Umar, A., Risinger, J. I., Lipford, J. R., Kane, M., Yin, S., Barrett, J. C., Kolodner, R. D. & Kunkel, T. A. (1995). Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res 55: 6063–6070.
Branch, P., Aquilina, G., Bignami, M. & Karran, P. (1993). Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature 362: 652–654.
Brasier, A. R., Tate, J. E. & Habener, J. F. (1989). Optimized use of the firefly luciferase assay as a reporter gene in mammalian cell lines. Biotechniques 7: 1116–1122.
Carethers, J. M., Hawn, M. T., Chauhan, D. P., Luce, M. C., Marra, G., Koi, M. & Boland, C. R. (1996). Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N′-nitro-N-nitrosoguanidine. J Clin Invest 98: 199–206.
Dijt, F. J., Fichtinger-Schepman, A. M., Berends, F. & Reedijk, J. (1988). Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. Cancer Res 48: 6058–6062.
Drummond, J. T., Anthoney, A., Brown, R. & Modrich, P. (1996). Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 271: 19645–19648.
Duckett, D. R., Drummond, J. T., Murchie, A. I., Reardon, J. T., Sancar, A., Lilley, D. M. & Modrich, P. (1996). Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. Proc Natl Acad Sci USA 93: 6443–6447.
Eastman, A. & Schulte, N. (1988). Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry 27: 4730–4734.
Fink, D., Nebel, S., Aebi, S., Zheng, H., Cenni, B., Nehme, A., Christen, R. D. & Howell, S. B. (1996). The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56: 4881–4886.
Fink, D., Zheng, H., Nebel, S., Norris, P. S., Aebi, S., Lin, T. P., Nehme, A., Christen, R. D., Haas, M., MacLeod, C. L. & Howell, S. B. (1997). In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 57: 1841–1845.
Gately, D. P. & Howell, S. B. (1993). Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 67: 1171–1176.
Hawn, M. T., Umar, A., Carethers, J. M., Marra, G., Kunkel, T. A., Boland, C. R. & Koi, M. (1995). Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res 55: 3721–3725.
Huang, J. C., Zamble, D. B., Reardon, J. T., Lippard, S. J. & Sancar, A. (1994). HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci USA 91: 10394–10398.
Jennerwein, M. M., Eastman, A. & Khokhar, A. R. (1991). The role of DNA repair in resistance of L1210 cells to isomeric 1,2-diaminocyclohexaneplatinum complexes and ultraviolet irradiation. Mutat Res 254: 89–96.
Jones, J. C., Zhen, W. P., Reed, E., Parker, R. J., Sancar, A. & Bohr, V. A. (1991). Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells. J Biol Chem 266: 7101–7107.
Karran, P. & Bignami, M. (1994). DNA damage tolerance, mismatch repair and genome instability. Bioessays 16: 833–839.
Kat, A., Thilly, W. G., Fang, W. H., Longley, M. J., Li, G. M. & Modrich, P. (1993). An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci USA 90: 6424–6428.
Koi, M., Umar, A., Chauhan, D. P., Cherian, S. P., Carethers, J. M., Kunkel, T. A. & Boland, C. R. (1994). Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation [published erratum appears in Cancer Res 1995 55: 201]. Cancer Res 54: 4308–4312.
Kolodner, R. D. (1995). Mismatch repair: mechanisms and relationship to cancer susceptibility. Trends Biochem Sci 20: 397–401.
May, A., Nairn, R. S., Okumoto, D. S., Wassermann, K., Stevnsner, T., Jones, J. C. & Bohr, V. A. (1993). Repair of individual DNA strands in the hamster dihydrofolate reductase gene after treatment with ultraviolet light, alkylating agents, and cisplatin. J Biol Chem 268: 1650–1657.
Mello, J. A., Lippard, S. J. & Essigmann, J. M. (1995). DNA adducts of cis-diamminedichloroplatinum(II) and its trans isomer inhibit RNA polymerase II differentially in vivo. Biochemistry 34: 14783–14791.
Mello, J. A., Acharya, S., Fishel, R. & Essigmann, J. M. (1996). The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem Biol 3: 579–589.
Mu, D., Tursun, M., Duckett, D. R., Drummond, J. T., Modrich, P. & Sancar, A. (1997). Recognition and repair of compound DNA lesions (base damage and mismatch) by human mismatch repair and excision repair systems. Mol Cell Biol 17: 760–769.
Parker, R. J., Eastman, A., Bostick-Bruton, F. & Reed, E. (1991). Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 87: 772–777.
Rittner, K., Stoeppler, H., Pawlita, M. & Sczakiel, G. (1991). Versatile eucaryotic vectors for strong and constitutive transient and stable gene expression. Methods Mol Cell Biol 2: 176–181.
Sheibani, N., Jennerwein, M. M. & Eastman, A. (1989). DNA repair in cells sensitive and resistant to cis-diamminedichloroplatinum(II): host cell reactivation of damaged plasmid DNA. Biochemistry 28: 3120–3124.
Umar, A., Koi, M., Risinger, J. I., Glaab, W., Tindall, K. R., Kolodner, R. D., Boland, C. R., Barrett, J. C. & Kunkel, T. A. (1997). Correction of hypermutability, N-methyl-N′-nitro-N-nitrosoguanidine-resistance and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. Cancer Res 57: 3949–3955.
Vaisman, A., Varchenko, M. & Chaney, S. G. (1997). Correlation between mismatch repair defects and increased replicative bypass in cisplatin resistant cell lines. Proc Am Assoc Cancer Res 38: 312
Vaisman, A., Varchenko, M., Umar, A., Kunkel, T. A., Risinger, J. I., Barrett, J. C. & Chaney, S. G. (1998). Defects in hMSH6, but not hMSH3, correlate with increased resistance and enhanced replicative bypass of cisplatin, but not oxaliplatin, adducts. Proc Am Assoc Cancer Res 39: 159
Zamble, D. B. & Lippard, S. J. (1995). Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 20: 435–439.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Cenni, B., Kim, HK., Bubley, G. et al. Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatin. Br J Cancer 80, 699–704 (1999). https://doi.org/10.1038/sj.bjc.6690412
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690412
Keywords
This article is cited by
-
One-milliliter wet-digestion for inductively coupled plasma mass spectrometry (ICP-MS): determination of platinum-DNA adducts in cells treated with platinum(II) complexes
Analytical and Bioanalytical Chemistry (2005)